We must prioritize early screening and diagnosis to facilitate timely interventions, prevent the progression to advanced liver disease and, ultimately, help save the lives of 1 in 10 Americans.
Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate.
Annual family premiums for employer-sponsored coverage reached $23,968 in 2023, according to a new KFF survey. Of that family premium total, workers are contributing $6,575 annually.
FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.
In an upcoming webinar, learn how informed awareness can help hospitals overcome their most challenging operational challenges to simultaneously improve efficiency, staff engagement and satisfaction, quality of care, and profitability.